GLP-1 agonists for smoking cessation and post-cessation weight management: A systematic review and meta-analysis of randomized trials.

While GLP-1 receptor agonists have revolutionized the treatment of diabetes and obesity, their role in smoking cessation remains inconclusive.

However, reductions in post-cessation weight and BMI highlight their potential as adjunctive agents to address weight-related relapse risk.

Larger, longer duration trials with newer GLP-1 agents are warranted to confirm these findings and clarify their role in smoking cessation.